Sildenafil |
First Choice
|
|
MHRA Drug Safety Update (Nov 2018): Sildenafil (Revatio and Viagra): reports of persistent pulmonary hypertension of the newborn (PPHN) following in-utero exposure in a clinical trial on intrauterine growth restriction |
|
Tadalafil |
Second Choice
|
|
NTAG: Daily vs on-demand phosphodiesterase-5 (PDE-5) inhibitors for the management of erectile dysfunction following treatment for prostate cancer |
|
Vardenafil |
Formulary
|
|
|
Alprostadil Vitaros® & Muse® |
Formulary
|
Treatment with alprostadil cream (Vitaros®) is NOT approved for use in County Durham and Tees Valley |
|